03/04
Headlines

Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Mark Doerr02 mins

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded…

Read More

Financial Stocks On the Move: Wells Fargo (NYSE:WFC), Bank of America Corporation (NYSE:BAC), JPMorgan Chase & Co. (NYSE:JPM)

Richard Atkins02 mins

Reports are out this morning that Wells Fargo (NYSE:WFC) is being accused by New York attorney general of fabricating foreclosure documents. Despite this the company’s shares are up 1.54% nearing the top end of the 52-week range. The company has a dividend yield of 1.20 and a price to earnings ration of 12.35. Wells Fargo…

Read More
FB Nasdaq FB Facebook

Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Mark DeFrance02 mins

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a…

Read More

Most Active Solar Stocks: JA Solar (NASDAQ:JASO), Yingli Green Energy (NYSE:YGE), First Solar (NASDAQ:FSLR), Solar City (NASDAQ:SCTY)

Mark DeFrance03 mins

JA Solar Holdings (NASDAQ:JASO) reached a more than two-year high Monday after reporting Q4 results that beat analyst estimates. The Chinese maker of solar cells reported non-GAAP earnings of RMB 0.94, or $0.16, per diluted ADS, compared with the Capital IQ estimate for a loss of $0.06 a share. Q4 net revenue grew 30% from…

Read More

Tech News

Tech Analysis & Market News

Skip to content ↓